Pharmacokinetics of the new potential antiparkinsonian agent ADK-1113 after different dosage regimens in mice

The pharmacokinetics of ADK-1113 were studied in mice treated with different dosage regimens. Objective. This study aimed to investigate ADK-1113 pharmacokinetics after multiple intraperitoneal administrations. Methods. This study was conducted on male outbred mice. The concentrations of ADK-1113 in the blood plasma were determined using high-performance liquid chromatography with mass-spectrometric detection. The pharmacokinetic parameters were evaluated using a model-independent method. Results. The test substance in the blood plasma was determined for 4 h after single and multiple (four times with a dosage interval of 2.8 h) intraperitoneal administrations at a dose of 10 mg/kg. ADK-1113 administration mode did not affect its half-life or mean residence time. ADK-1113 did not accumulate in mice.